APO Research
Talk to an analyst

APO RESEARCH · REPORT

Duvelisib for Relapsed CLL/SLL

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Duvelisib for Relapsed CLL/SLL Market Outlook and Growth Opportunities 2026

26 December 2025194 pages

Choose your research edition.

Industry ResearchDuvelisib for Relapsed CLL/SLL Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Duvelisib for Relapsed CLL/SLL Industry Growth and Trends Forecast to 203271 pages · $3,450 USDMarket StructureGlobal Duvelisib for Relapsed CLL/SLL Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032173 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Duvelisib for Relapsed CLL/SLL Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Duvelisib for Relapsed CLL/SLL Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Duvelisib for Relapsed CLL/SLL market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Duvelisib for Relapsed CLL/SLL is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Duvelisib for Relapsed CLL/SLL is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Duvelisib for Relapsed CLL/SLL is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Duvelisib for Relapsed CLL/SLL market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Duvelisib for Relapsed CLL/SLL market include Secura Bio and CSPC among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Duvelisib for Relapsed CLL/SLL market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Duvelisib for Relapsed CLL/SLL and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Duvelisib for Relapsed CLL/SLL sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Duvelisib for Relapsed CLL/SLL market size, projected growth trends, production technologies, key applications, and end-use industries.

Duvelisib for Relapsed CLL/SLL Segment by Company

Secura Bio

CSPC

Duvelisib for Relapsed CLL/SLL Segment by Type

25mg

15mg

Duvelisib for Relapsed CLL/SLL Segment by Application

Chronic Lymphocytic Leukemia (CLL)

Small Lymphocytic Lymphoma (SLL)

Duvelisib for Relapsed CLL/SLL Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Duvelisib for Relapsed CLL/SLL status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Duvelisib for Relapsed CLL/SLL market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Duvelisib for Relapsed CLL/SLL significant trends, drivers, influence factors in global and regions.

6. To analyze Duvelisib for Relapsed CLL/SLL competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duvelisib for Relapsed CLL/SLL market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Duvelisib for Relapsed CLL/SLL and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duvelisib for Relapsed CLL/SLL.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Duvelisib for Relapsed CLL/SLL market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Duvelisib for Relapsed CLL/SLL industry.

Chapter 3: Detailed analysis of Duvelisib for Relapsed CLL/SLL manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Duvelisib for Relapsed CLL/SLL in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Duvelisib for Relapsed CLL/SLL in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Duvelisib for Relapsed CLL/SLL Industry Trends Table 2. Duvelisib for Relapsed CLL/SLL Industry Drivers Table 3. Duvelisib for Relapsed CLL/SLL Industry Opportunities and Challenges Table 4. Duvelisib for Relapsed CLL/SLL Industry Restraints Table 5. Global Duvelisib for Relapsed CLL/SLL Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Duvelisib for Relapsed CLL/SLL Revenue Share by Company (2021-2026) Table 7. Global Duvelisib for Relapsed CLL/SLL Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Duvelisib for Relapsed CLL/SLL Sales Volume Share by Company (2021-2026) Table 9. Global Duvelisib for Relapsed CLL/SLL Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Duvelisib for Relapsed CLL/SLL Company Ranking, (2024-2026) & (USD Million) Table 11. Global Duvelisib for Relapsed CLL/SLL Key Company Manufacturing Base & Headquarters Table 12. Global Duvelisib for Relapsed CLL/SLL Company, Product Type & Application Table 13. Global Duvelisib for Relapsed CLL/SLL Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Duvelisib for Relapsed CLL/SLL by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 25mg Table 18. Significant Companies of 15mg Table 19. Global Duvelisib for Relapsed CLL/SLL Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Duvelisib for Relapsed CLL/SLL Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Duvelisib for Relapsed CLL/SLL Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Duvelisib for Relapsed CLL/SLL Sales Volume Share by Type (2021-2026) Table 23. Global Duvelisib for Relapsed CLL/SLL Sales Volume Share by Type (2027-2032) Table 24. Global Duvelisib for Relapsed CLL/SLL Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Duvelisib for Relapsed CLL/SLL Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Duvelisib for Relapsed CLL/SLL Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Duvelisib for Relapsed CLL/SLL Sales Value Share by Type (2021-2026) Table 28. Global Duvelisib for Relapsed CLL/SLL Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Chronic Lymphocytic Leukemia (CLL) Table 30. Significant Companies of Small Lymphocytic Lymphoma (SLL) Table 31. Global Duvelisib for Relapsed CLL/SLL Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Duvelisib for Relapsed CLL/SLL Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Duvelisib for Relapsed CLL/SLL Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Duvelisib for Relapsed CLL/SLL Sales Volume Share by Application (2021-2026) Table 35. Global Duvelisib for Relapsed CLL/SLL Sales Volume Share by Application (2027-2032) Table 36. Global Duvelisib for Relapsed CLL/SLL Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Duvelisib for Relapsed CLL/SLL Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Duvelisib for Relapsed CLL/SLL Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Duvelisib for Relapsed CLL/SLL Sales Value Share by Application (2021-2026) Table 40. Global Duvelisib for Relapsed CLL/SLL Sales Value Share by Application (2027-2032) Table 41. Global Duvelisib for Relapsed CLL/SLL Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Duvelisib for Relapsed CLL/SLL Sales by Region (2021-2026) & (K Units) Table 43. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Region (2021-2026) Table 44. Global Duvelisib for Relapsed CLL/SLL Sales by Region (2027-2032) & (K Units) Table 45. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Region (2027-2032) Table 46. Global Duvelisib for Relapsed CLL/SLL Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Duvelisib for Relapsed CLL/SLL Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Duvelisib for Relapsed CLL/SLL Sales Value Share by Region (2021-2026) Table 49. Global Duvelisib for Relapsed CLL/SLL Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Duvelisib for Relapsed CLL/SLL Sales Value Share by Region (2027-2032) Table 51. Global Duvelisib for Relapsed CLL/SLL Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Duvelisib for Relapsed CLL/SLL Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Duvelisib for Relapsed CLL/SLL Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Duvelisib for Relapsed CLL/SLL Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Duvelisib for Relapsed CLL/SLL Sales by Country (2021-2026) & (K Units) Table 56. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Country (2021-2026) Table 57. Global Duvelisib for Relapsed CLL/SLL Sales by Country (2027-2032) & (K Units) Table 58. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Country (2027-2032) Table 59. Global Duvelisib for Relapsed CLL/SLL Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Duvelisib for Relapsed CLL/SLL Sales Value Market Share by Country (2021-2026) Table 61. Global Duvelisib for Relapsed CLL/SLL Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Duvelisib for Relapsed CLL/SLL Sales Value Market Share by Country (2027-2032) Table 63. Secura Bio Company Information Table 64. Secura Bio Business Overview Table 65. Secura Bio Duvelisib for Relapsed CLL/SLL Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Secura Bio Duvelisib for Relapsed CLL/SLL Product Portfolio Table 67. Secura Bio Recent Development Table 68. CSPC Company Information Table 69. CSPC Business Overview Table 70. CSPC Duvelisib for Relapsed CLL/SLL Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. CSPC Duvelisib for Relapsed CLL/SLL Product Portfolio Table 72. CSPC Recent Development Table 73. Key Raw Materials Table 74. Raw Materials Key Suppliers Table 75. Duvelisib for Relapsed CLL/SLL Distributors List Table 76. Duvelisib for Relapsed CLL/SLL Customers List Table 77. Research Programs/Design for This Report Table 78. Authors List of This Report Table 79. Secondary Sources Table 80. Primary Sources List of Figures Figure 1. Duvelisib for Relapsed CLL/SLL Product Image Figure 2. Global Duvelisib for Relapsed CLL/SLL Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Duvelisib for Relapsed CLL/SLL Sales Value (2021-2032) & (US$ Million) Figure 4. Global Duvelisib for Relapsed CLL/SLL Sales (2021-2032) & (K Units) Figure 5. Global Duvelisib for Relapsed CLL/SLL Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Duvelisib for Relapsed CLL/SLL Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 25mg Image Figure 10. 15mg Image Figure 11. Global Duvelisib for Relapsed CLL/SLL Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Duvelisib for Relapsed CLL/SLL Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Duvelisib for Relapsed CLL/SLL Sales Volume Share by Type (2021-2032) Figure 14. Global Duvelisib for Relapsed CLL/SLL Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Duvelisib for Relapsed CLL/SLL Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Duvelisib for Relapsed CLL/SLL Sales Value Share by Type (2021-2032) Figure 17. Chronic Lymphocytic Leukemia (CLL) Image Figure 18. Small Lymphocytic Lymphoma (SLL) Image Figure 19. Global Duvelisib for Relapsed CLL/SLL Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Duvelisib for Relapsed CLL/SLL Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Duvelisib for Relapsed CLL/SLL Sales Volume Share by Application (2021-2032) Figure 22. Global Duvelisib for Relapsed CLL/SLL Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Duvelisib for Relapsed CLL/SLL Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Duvelisib for Relapsed CLL/SLL Sales Value Share by Application (2021-2032) Figure 25. Global Duvelisib for Relapsed CLL/SLL Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Duvelisib for Relapsed CLL/SLL Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Duvelisib for Relapsed CLL/SLL Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Duvelisib for Relapsed CLL/SLL Sales Value (2021-2032) & (US$ Million) Figure 30. North America Duvelisib for Relapsed CLL/SLL Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Duvelisib for Relapsed CLL/SLL Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Duvelisib for Relapsed CLL/SLL Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Duvelisib for Relapsed CLL/SLL Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Duvelisib for Relapsed CLL/SLL Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Duvelisib for Relapsed CLL/SLL Sales Value (2021-2032) & (US$ Million) Figure 36. South America Duvelisib for Relapsed CLL/SLL Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Duvelisib for Relapsed CLL/SLL Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Duvelisib for Relapsed CLL/SLL Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Duvelisib for Relapsed CLL/SLL Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Duvelisib for Relapsed CLL/SLL Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 25mg
  • 15mg
Applications
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
Companies covered
  • Secura Bio
  • CSPC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Duvelisib for Relapsed CLL/SLL Sales Value (2021-2032)
  4. 1.2.2 Global Duvelisib for Relapsed CLL/SLL Sales Volume (2021-2032)
  5. 1.2.3 Global Duvelisib for Relapsed CLL/SLL Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Duvelisib for Relapsed CLL/SLL Market Dynamics
  1. 2.1 Duvelisib for Relapsed CLL/SLL Industry Trends
  2. 2.2 Duvelisib for Relapsed CLL/SLL Industry Drivers
  3. 2.3 Duvelisib for Relapsed CLL/SLL Industry Opportunities and Challenges
  4. 2.4 Duvelisib for Relapsed CLL/SLL Industry Restraints
3 Duvelisib for Relapsed CLL/SLL Market by Company
  1. 3.1 Global Duvelisib for Relapsed CLL/SLL Company Revenue Ranking in 2025
  2. 3.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Company (2021-2026)
  3. 3.3 Global Duvelisib for Relapsed CLL/SLL Sales Volume by Company (2021-2026)
  4. 3.4 Global Duvelisib for Relapsed CLL/SLL Average Price by Company (2021-2026)
  5. 3.5 Global Duvelisib for Relapsed CLL/SLL Company Ranking (2024-2026)
  6. 3.6 Global Duvelisib for Relapsed CLL/SLL Company Manufacturing Base and Headquarters
  7. 3.7 Global Duvelisib for Relapsed CLL/SLL Company Product Type and Application
  8. 3.8 Global Duvelisib for Relapsed CLL/SLL Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Duvelisib for Relapsed CLL/SLL Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Duvelisib for Relapsed CLL/SLL Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Duvelisib for Relapsed CLL/SLL Market by Type
  1. 4.1 Duvelisib for Relapsed CLL/SLL Type Introduction
  2. 4.1.1 25mg
  3. 4.1.2 15mg
  4. 4.2 Global Duvelisib for Relapsed CLL/SLL Sales Volume by Type
  5. 4.2.1 Global Duvelisib for Relapsed CLL/SLL Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Duvelisib for Relapsed CLL/SLL Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Duvelisib for Relapsed CLL/SLL Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Duvelisib for Relapsed CLL/SLL Sales Value by Type
  9. 4.3.1 Global Duvelisib for Relapsed CLL/SLL Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Duvelisib for Relapsed CLL/SLL Sales Value by Type (2021-2032)
  11. 4.3.3 Global Duvelisib for Relapsed CLL/SLL Sales Value Share by Type (2021-2032)
5 Duvelisib for Relapsed CLL/SLL Market by Application
  1. 5.1 Duvelisib for Relapsed CLL/SLL Application Introduction
  2. 5.1.1 Chronic Lymphocytic Leukemia (CLL)
  3. 5.1.2 Small Lymphocytic Lymphoma (SLL)
  4. 5.2 Global Duvelisib for Relapsed CLL/SLL Sales Volume by Application
  5. 5.2.1 Global Duvelisib for Relapsed CLL/SLL Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Duvelisib for Relapsed CLL/SLL Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Duvelisib for Relapsed CLL/SLL Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Duvelisib for Relapsed CLL/SLL Sales Value by Application
  9. 5.3.1 Global Duvelisib for Relapsed CLL/SLL Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Duvelisib for Relapsed CLL/SLL Sales Value by Application (2021-2032)
  11. 5.3.3 Global Duvelisib for Relapsed CLL/SLL Sales Value Share by Application (2021-2032)
6 Duvelisib for Relapsed CLL/SLL Regional Sales and Value Analysis
  1. 6.1 Global Duvelisib for Relapsed CLL/SLL Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Duvelisib for Relapsed CLL/SLL Sales by Region (2021-2032)
  3. 6.2.1 Global Duvelisib for Relapsed CLL/SLL Sales by Region: 2021-2026
  4. 6.2.2 Global Duvelisib for Relapsed CLL/SLL Sales by Region (2027-2032)
  5. 6.3 Global Duvelisib for Relapsed CLL/SLL Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Duvelisib for Relapsed CLL/SLL Sales Value by Region (2021-2032)
  7. 6.4.1 Global Duvelisib for Relapsed CLL/SLL Sales Value by Region: 2021-2026
  8. 6.4.2 Global Duvelisib for Relapsed CLL/SLL Sales Value by Region (2027-2032)
  9. 6.5 Global Duvelisib for Relapsed CLL/SLL Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Duvelisib for Relapsed CLL/SLL Sales Value (2021-2032)
  12. 6.6.2 North America Duvelisib for Relapsed CLL/SLL Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Duvelisib for Relapsed CLL/SLL Sales Value (2021-2032)
  15. 6.7.2 Europe Duvelisib for Relapsed CLL/SLL Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Duvelisib for Relapsed CLL/SLL Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Duvelisib for Relapsed CLL/SLL Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Duvelisib for Relapsed CLL/SLL Sales Value (2021-2032)
  21. 6.9.2 South America Duvelisib for Relapsed CLL/SLL Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Duvelisib for Relapsed CLL/SLL Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Duvelisib for Relapsed CLL/SLL Sales Value Share by Country, 2025 VS 2032
7 Duvelisib for Relapsed CLL/SLL Country-level Sales and Value Analysis
  1. 7.1 Global Duvelisib for Relapsed CLL/SLL Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Duvelisib for Relapsed CLL/SLL Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Duvelisib for Relapsed CLL/SLL Sales by Country (2021-2032)
  4. 7.3.1 Global Duvelisib for Relapsed CLL/SLL Sales by Country (2021-2026)
  5. 7.3.2 Global Duvelisib for Relapsed CLL/SLL Sales by Country (2027-2032)
  6. 7.4 Global Duvelisib for Relapsed CLL/SLL Sales Value by Country (2021-2032)
  7. 7.4.1 Global Duvelisib for Relapsed CLL/SLL Sales Value by Country (2021-2026)
  8. 7.4.2 Global Duvelisib for Relapsed CLL/SLL Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Duvelisib for Relapsed CLL/SLL Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Duvelisib for Relapsed CLL/SLL Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Duvelisib for Relapsed CLL/SLL Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Secura Bio
  2. 8.1.1 Secura Bio Company Information
  3. 8.1.2 Secura Bio Business Overview
  4. 8.1.3 Secura Bio Duvelisib for Relapsed CLL/SLL Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Secura Bio Duvelisib for Relapsed CLL/SLL Product Portfolio
  6. 8.1.5 Secura Bio Recent Developments
  7. 8.2 CSPC
  8. 8.2.1 CSPC Company Information
  9. 8.2.2 CSPC Business Overview
  10. 8.2.3 CSPC Duvelisib for Relapsed CLL/SLL Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CSPC Duvelisib for Relapsed CLL/SLL Product Portfolio
  12. 8.2.5 CSPC Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Duvelisib for Relapsed CLL/SLL Value Chain Analysis
  2. 9.1.1 Duvelisib for Relapsed CLL/SLL Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Duvelisib for Relapsed CLL/SLL Sales Mode & Process
  6. 9.2 Duvelisib for Relapsed CLL/SLL Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Duvelisib for Relapsed CLL/SLL Distributors
  9. 9.2.3 Duvelisib for Relapsed CLL/SLL Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst